Amplicore develops injectable regenerative therapeutics that repair and restore joint and spine tissues affected by osteoarthritis, cartilage damage, disc degeneration, and meniscus tears. Their proprietary minimally invasive formulations are designed for intra‑articular delivery in outpatient settings, enabling physicians to target the underlying pathology rather than just relieve pain.
Funding
$37M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Degenerative musculoskeletal disorders such as osteoarthritis, cartilage damage, disc degeneration, and meniscus tears are typically managed with pain‑relieving drugs or invasive surgeries, which do not restore damaged tissue and often leave patients with persistent disability.
Solution
Amplicore develops injectable regenerative therapeutics that aim to repair and restore joint tissues rather than merely alleviate pain. Their proprietary formulation is designed for minimally invasive delivery directly into the affected joint, enabling targeted action on the underlying pathology. By leveraging a novel biopharmaceutical platform, the treatments promote tissue regeneration and functional improvement in conditions that currently have limited disease‑modifying options. The approach is intended to be compatible with standard clinical workflows, allowing physicians to administer the therapy in outpatient settings.
Target Audience
Primary customers are orthopedic surgeons, sports medicine physicians, and rheumatologists treating patients with degenerative joint and spine conditions who seek disease‑modifying, minimally invasive therapies.
Features
- Injectable formulation optimized for intra‑articular delivery to degenerated joints
- Proprietary regenerative technology that stimulates cartilage and disc tissue repair
- Minimally invasive administration requiring only standard injection techniques
- Broad applicability across multiple musculoskeletal indications, including osteoarthritis, cartilage lesions, degenerative disc disease, and acute meniscus tears
- Designed for outpatient use, facilitating integration into existing orthopedic and rheumatology practice routines